Related by context. All words. (Click for frequent words.) 68 ALT flares 67 stage IIIb IV 67 lymphoid blast 67 Infusion reactions 67 phase Ph + 66 leukemia AML 66 relapsed MM 66 biochemical relapse 66 MCyR 66 leukemia ALL 66 hepatorenal syndrome 66 prior chemotherapy regimens 65 achieved CCyR 65 AGILECT R 65 8mg/kg 65 anthracycline taxane 65 Infusion Reactions Severe 65 KRAS mutant tumors 65 cytogenetic responses 65 hematologic toxicity 65 receiving XGEVA 65 relapsed Acute Myeloid 64 mitoxantrone plus 64 refractory NSCLC 64 hypophosphatemia 64 BARACLUDE ® 64 PASI scores 64 leukemia APL 64 bone marrow reticulin deposition 64 metastatic renal cell 64 acute GvHD 64 virologic failure 64 PLX STROKE targeting 64 bortezomib refractory 63 dasatinib Sprycel ® 63 antiretroviral naive 63 anthracyclines taxanes 63 leucopenia 63 renal flares 63 Hormone Refractory Prostate Cancer 63 CCyR 63 CYT# potent vascular disrupting 63 SPRYCEL ® 63 REYATAZ r arm 63 response CCyR 63 myeloid blast 63 Febrile neutropenia 63 recurrent glioblastoma multiforme 63 taxane chemotherapy administered 63 PREZISTA r arm 63 CLL SLL 63 Fludarabine 63 cytogenetic response 63 achieved ACR# 62 interferon ribavirin 62 antiretroviral naïve 62 EDSS scores 62 LymphoStat B belimumab 62 Hypertensive adverse reactions 62 severe neutropenia 62 myelodysplastic myeloproliferative diseases 62 decompensated liver disease 62 anemia neutropenia 62 trastuzumab Herceptin ® 62 ALT elevation 62 receptor tyrosine kinase inhibitor 62 venlafaxine ER 62 HBeAg negative 62 receiving prophylactic anticoagulation 62 heavily pretreated 62 plus OBT 62 HER2 overexpression 62 EOquin TM phase 62 carcinoma mCRC 62 autoantibody positive 62 cytopenias 62 refractory AML 62 FOLFIRI alone 62 treatment naive genotype 62 stage IIIB 62 opioid naive 62 chronic eosinophilic leukemia 62 recombinant PSMA vaccine 62 Scale EDSS 62 EGFR mutation positive 61 refractory indolent non 61 nilotinib Tasigna ® 61 metastatic kidney 61 resistant hormone refractory 61 Severe hypersensitivity reactions 61 mcg BID 61 plus dexamethasone 61 deep venous thromboses 61 irinotecan containing 61 Follicular Lymphoma 61 plus prednisone prednisolone 61 anthracycline containing 61 Folfox 61 acute leukemias 61 Hypotension 61 sarcoma melanoma 61 flutamide 61 neutropenia dehydration dyspnea 61 dexamethasone Decadron 61 tumors GIST 61 Acute myeloid leukemia 61 plus methotrexate 61 gout flares 61 recurrent NSCLC 61 aminotransferases 61 receiving VICTRELIS 61 underwent resection 61 CR nPR 61 EXJADE 61 prednisone prednisolone plus 61 receiving golimumab 61 Biogen Genentech 61 serum aminotransferase levels 61 treatment naïve genotype 61 recurrent VTE 61 PSADT 61 ® lenalidomide 61 relapsed refractory multiple myeloma 61 AML MDS 61 pyrexia mucositis sepsis febrile 61 anaphylactic reactions bronchospasm 61 morphometric vertebral fractures 61 smoldering multiple myeloma 61 elevated transaminases 61 haematologic 61 intravascular hemolysis 61 HbA 1c levels 61 Ph + acute lymphoblastic 61 papillary renal cell carcinoma 61 lenalidomide Revlimid R 61 systemic anaplastic large 61 fibrinolysis 61 Thrombotic events 61 virological response 61 following antiestrogen therapy 61 TM pralatrexate injection 61 receiving INTRON 61 refractory chronic myeloid 60 #mg BID [001] 60 doxorubicin cyclophosphamide 60 TNF antagonist 60 relapsing remitting MS RRMS 60 mL/min/#.# m 2 60 refractory CLL 60 ACTEMRA TM 60 progression TTP 60 Dose escalation 60 cisplatin chemotherapy 60 hypertrichosis occurred 60 biologic DMARD 60 smoldering myeloma 60 FluCAM 60 adefovir treated 60 Flu Cy 60 nucleoside naive 60 follicular lymphomas 60 receiving immunosuppressive therapy 60 desvenlafaxine succinate 60 Sustained Virological Response 60 overt nephropathy 60 cyclophosphamide chemotherapy 60 dosing cohort 60 aspartate aminotransferase AST 60 liver enzymes ALT 60 nutlin 3a 60 CrCl 60 non metastatic osteosarcoma 60 advanced adenoma 60 dasatinib Sprycel 60 underwent surgical resection 60 lymphocytosis 60 peripheral sensory neuropathy 60 oral nucleoside analogue 60 formerly LymphoStat B 60 Mg Usa 60 refractory CTCL 60 -#.# log# 60 Stage IIB 60 MDS AML 60 moderate renal impairment 60 thrombocytopenia neutropenia 60 FUSILEV enhances 60 HBeAg negative patients 60 basal cell carcinoma BCC 60 systemic ALCL 60 #mg/day [002] 60 metastatic malignant 60 dosing cohorts 60 Newly Diagnosed Multiple Myeloma 60 annualized relapse 60 placebo dexamethasone 60 Budesonide foam crofelemer 60 TTR amyloidosis 60 colorectal adenoma 60 alanine aminotransferase ALT 60 APTIVUS r 60 complete cytogenetic response 60 K ras mutations 60 docetaxel chemotherapy 60 Refractory Hodgkin Lymphoma 60 apolipoprotein E4 60 chlorambucil 60 HIV coinfected 60 estramustine 60 preintervention 60 naïve HCV 60 pegylated interferon peg IFN 60 imatinib therapy 60 virological failure 60 adjunctive placebo 60 KRAS mutations occur 60 4mg/kg 60 EDSS score 60 mCRPC 60 completely resected 60 cirrhotic CHC monoinfected patients 60 DOXIL ® 60 dysplastic lesions 60 recurrent malignant glioma 60 glycated hemoglobin levels 60 lopinavir r arm 59 Brentuximab Vedotin SGN 59 phase IIb study 59 C1 INH deficiency 59 % CI #.#-#.# [003] 59 echinacea tablets 59 mg kg dose 59 non splenectomized 59 HBeAg positive patients 59 hours postdose 59 chronic GVHD 59 pT3 59 cytoreduction 59 plus aztreonam 59 dasatinib 59 maximal doses 59 Cutaneous T 59 Toxicities 59 PSA nadir 59 sensory neuropathy 59 eosinophilic asthma 59 MS relapses 59 refractory cutaneous T 59 Acute Myeloid Leukaemia AML 59 histologically confirmed 59 lymphocytic leukemia 59 T2DM 59 refractory ovarian cancer 59 PAOD 59 Immune reconstitution syndrome 59 #mg QD [002] 59 aminotransferase elevations greater 59 postintervention 59 T1c 59 dacarbazine DTIC 59 baminercept 59 prednisone prednisolone 59 recurrent atrial fibrillation 59 nonmetastatic 59 Amgen Neulasta R 59 hepatic fibrosis 59 curative resection 59 hypomagnesemia 59 generalized seizures 59 Myelodysplastic Syndrome MDS 59 reduce serum phosphate 59 metastatic renal cell carcinoma 59 neurologic progression 59 atazanavir ritonavir 59 alfa 2a 59 adjunctive ABILIFY 59 AZT zidovudine Retrovir 59 pulmonary exacerbations 59 myelodysplastic syndrome MDS 59 advanced adenomas 59 delayed CINV 59 Diffuse Large B 59 postoperative chemotherapy 59 placebo dummy pill 59 Thrombotic thromboembolic complications 59 graft occlusion 59 rapid virologic response 59 relapsing remitting 59 alanine aminotransferase 59 Operative mortality 59 demonstrated antitumor activity 59 elevated ALT 59 receiving VELCADE 59 humanized interleukin 6 59 gemcitabine carboplatin 59 psoriatic arthritis PsA 59 severely active polyarticular 59 hematological toxicity 59 MULTAQ 59 QTcF 59 Postoperative complications 59 dose escalation phase 59 cytarabine daunorubicin 59 refractory gout 59 rALLy 59 leukemia CLL 59 CML CP 59 Xelox 59 IMiDs 59 de novo kidney transplant 59 ribavirin RBV 59 severe oral mucositis 59 cerebrovascular events 59 FOLFOX4 alone 59 adriamycin 59 ribavirin therapy 59 generalized edema 59 refractory rituximab naive 59 Hepatocellular Carcinoma HCC 59 recurrent glioblastoma 59 EGFR TKI 59 proliferative retinopathy 59 Brain metastases 59 hypercholesterolemic patients 59 patient derived xenografts 59 genotypic resistance 59 Waldenstrom macroglobulinemia 59 biliary tract cancer 59 perioperatively 59 elevated serum creatinine 59 undetectable virus HCV 59 metastatic bladder 59 severe exacerbations 59 NMIBC 59 ancrod 59 detectable HCV RNA 59 advanced carcinoid 59 progressive PsA 59 umol L 59 imatinib resistant 59 erlotinib Tarceva ® 59 oral vancomycin 58 Thrombocytopenia 58 certolizumab 58 TEAEs 58 cabazitaxel 58 achieved sustained virological 58 remission induction 58 5-FU/LV 58 pilocytic astrocytoma 58 RRMS patients 58 infliximab monotherapy 58 CHD CVD 58 Postoperatively 58 % CI #.#-#.# [007] 58 inflammatory PDE 58 primary generalized tonic 58 mcg QD 58 HBeAg seroconversion 58 hour bronchodilation 58 diabetic kidney 58 Telintra 58 HCV RESPOND 2 58 Acute Myeloid Leukaemia 58 symptomatic pulmonary embolism 58 preoperative chemotherapy 58 PRADAXA #mg 58 HER2 positive metastatic breast 58 Ph + ALL 58 taxane chemotherapy 58 mg administered orally 58 recurrent genital herpes 58 PegIFN RBV 58 VELCADE melphalan 58 Acute leukemia 58 refractory chronic lymphocytic 58 paclitaxel cisplatin 58 refractory ischemia 58 serum phosphorous 58 Acute Myelogenous Leukemia AML 58 HBeAg + 58 plasma HCV RNA 58 Thal Dex 58 Erythropoietic therapies may 58 gastrointestinal stromal tumors GIST 58 neutropenic sepsis 58 HBeAg 58 ara C 58 Non Alcoholic Steatohepatitis 58 mcg kg REBETOL 58 cART 58 nondiabetic patients 58 plus prednisone 58 Index CDAI score 58 del 5q MDS 58 Mg Uk 58 CR CRu 58 complete cytogenetic 58 seminomas 58 serologically active systemic lupus 58 aspartate aminotransferase 58 Suppository Hydrocortisone Acetate Rectal 58 metformin accumulation 58 delayed onset CINV 58 refractory myeloma 58 elotuzumab 58 PROCTOCORT ® Suppository Hydrocortisone 58 Index CDAI 58 Chronic myeloid leukemia 58 heFH 58 Stent thrombosis 58 recurrent metastatic 58 undergone splenectomy 58 heavily pretreated patients 58 imatinib Gleevec ® 58 telaprevir dosed 58 metastatic renal 58 antiandrogen 58 atrioventricular block 58 CIMZIA TM 58 refractory metastatic 58 rituximab refractory 58 novel VDA molecule 58 neurogenic orthostatic hypotension NOH 58 progesterone receptor negative 58 indolent follicular non 58 Relapsed Refractory 58 log# copies mL 58 cetuximab Erbitux R 58 refractory indolent NHL 58 Gleevec imatinib mesylate 58 overt hepatic encephalopathy HE 58 mRCC 58 hepatic enzymes 58 hepatitis C genotype 58 mso tstyle colband size 58 comparator arm 58 Sustained virologic response 58 ER CHOP 58 partial remissions 58 mg QD 58 neuropathy sensory 58 sunitinib Sutent ® 58 baseline LDH 58 Pharmacokinetics PK 58 Symptom onset 58 pulmonary exacerbation 58 DAS# remission 58 invasive aspergillosis 58 virologic responses 58 steroid refractory ulcerative 58 Acute Myelogenous Leukemia 58 approved incretin mimetic 58 unresectable stage 58 Hodgkin lymphoma HL 58 Ishak fibrosis score 58 brand ciclesonide HFA 58 Median progression 58 RLAI 58 HBeAg positive 58 severe hypoglycaemia 58 used DNA alkylating 58 huN# DM1 58 PREZISTA r 58 Retreatment 58 Ph + CP 58 reinfarction 58 ipsilateral stroke 58 indolent NHL 58 Leukemia AML 58 Relapsing Remitting Multiple Sclerosis 58 q#h 58 virologic response 58 TO AVOID PREGNANCY WHILE 58 non hematological toxicities 58 AVASTIN 58 leukemia CML 58 TTF Therapy 58 nucleotide analog 58 gemcitabine Gemzar ® 58 nicardipine 58 Chronic ITP 57 evaluating T DM1 57 cerebrovascular accidents 57 endometrial carcinoma 57 differentiated thyroid 57 NNT = 57 hypereosinophilic syndrome 57 HBV infections 57 hematologic adverse reactions 57 decompensated cirrhosis 57 achieved sustained virologic 57 FCordero Milwaukee 57 q8h 57 idiopathic thrombocytopenic purpura ITP 57 disease progression 57 Free Survival PFS 57 low dose cytarabine 57 DMARD therapy 57 p#HER# positive 57 bisoprolol 57 adalimumab Humira 57 pegylated interferon alpha 57 liver decompensation 57 FOLFOX4 57 androgen suppression 57 lymphoid malignancies 57 coinfected 57 paroxysmal AF 57 Acute lymphocytic leukemia 57 abiraterone acetate 57 sustained virological response 57 vincristine doxorubicin 57 diabetes mellitus DM 57 oral FTY# 57 interferon beta therapy 57 asymptomatic carotid stenosis 57 liver histology 57 renal cell carcinomas 57 #mg dose [002] 57 opioid induced constipation OIC 57 follicular lymphoma FL 57 Telik logo TELINTRA 57 CTAP# Capsules 57 Subgroup analysis 57 macroalbuminuria 57 -#.# log# copies mL 57 TNF blocker therapy 57 Adjuvant chemotherapy 57 PEGINTRON TM 57 external genital lesions 57 metastatic RCC 57 neutropenia thrombocytopenia 57 Xeloda ® 57 diabetic gastroparesis 57 metastatic CRC 57 sustained virologic response 57 familial amyloidotic polyneuropathy FAP 57 hematologic abnormalities 57 Bezielle 57 divalproex sodium 57 gastrointestinal stromal tumor GIST 57 lupus erythematosus 57 mg q#h 57 EGFR expressing 57 asymptomatic PAD 57 Fasting blood glucose 57 lactate dehydrogenase 57 amisulpride 57 E1 INT TM 57 follicular Non Hodgkin 57 mso tstyle rowband size 57 acute myelogenous leukemia AML 57 Serious adverse reactions 57 metastatic GIST 57 e antigen HBeAg 57 onset diabetes mellitus 57 unresectable tumors 57 prospectively stratified 57 Dasatinib 57 underwent liver transplantation 57 unresectable Stage III 57 proliferative diabetic retinopathy 57 azilsartan medoxomil 57 humanized therapeutic 57 lintuzumab SGN 57 cytotoxic therapy 57 remission CR 57 minimally symptomatic metastatic castrate 57 basal cell carcinoma squamous 57 Pooled Analysis 57 paricalcitol 57 galiximab 57 alanine transaminase ALT 57 splenectomized patients 57 visceral metastases 57 CRp 57 metastatic malignant melanoma 57 induce remission 57 Philadelphia Chromosome Positive 57 Cell Lymphoma CTCL 57 paresthesias 57 Gleevec resistant 57 rimonabant #mg/day 57 IV NSCLC 57 BENICAR HCT 57 definite stent thrombosis 57 metastatic gastric 57 CIN3 57 Platelet counts 57 JAK2 V#F 57 preoperative intraoperative 57 herpes zoster shingles 57 Soliris therapy 57 NEUPOGEN 57 chronic myeloid 57 insulin glulisine 57 daunorubicin 57 mg/m2 dose 57 serum phosphate 57 pyelonephritis 57 osteosarcomas 57 placebo PBO 57 concomitant antibiotics 57 experienced hypomagnesemia 57 Bcr Abl T#I mutation 57 medically inoperable 57 idiopathic thrombocytopenic purpura 57 MADRS score 57 cyclophosphamide methotrexate 57 refractory DLBCL 57 ALT elevations 57 glycosylated hemoglobin levels 57 Juvenile Idiopathic Arthritis 57 stage IIIB IV 57 weekly subcutaneous injections 57 unfavorable cytogenetics 57 upon rechallenge 57 chronic HCV genotype 57 postoperative AF 57 storied chateau 57 pancreatic NET 57 fluoxetine paroxetine 57 Glioblastoma Multiforme 57 #mg ATC 57 transaminase levels 57 hepatocellular carcinomas 57 epithelial ovarian 57 intravenous belinostat 57 immune thrombocytopenic purpura ITP 57 relapsed ALL 57 venlafaxine XR 57 glipizide plus 57 primary hypercholesterolemia 57 R Saizen R 57 metastatic dermatofibrosarcoma protuberans DFSP 57 vascular occlusive diseases 57 Pulse CO Oximetry Pulse 57 torsade de pointes 57 events TEAEs 57 CIMZIA ™ 57 tumor regressions 57 refractory Hodgkin 57 idarubicin 57 recurrent metastatic ovarian cancer 57 Doxil ® 57 Myelodysplastic Syndrome 57 FOLFOX6 57 prior nephrectomy 57 evaluable subjects 57 dopaminergic therapy 57 myelofibrosis polycythemia vera 57 paclitaxel Taxol R 57 PCNSL 57 undetectable hepatitis C 57 naive HCV 57 XIENCE V PROMUS Stent 57 #.#ng/ml 57 mu opioid receptor antagonist 57 nonmetastatic prostate cancer 57 anterior uveitis 56 Decitabine 56 mCRC patients 56 virologically suppressed 56 paraprotein 56 oral antidiabetic agents 56 RhuDex TM 56 induce orthostatic hypotension 56 INSPIRE Trial Phase III 56 interferon beta 1a infertility 56 FOLFIRI 56 PEGylated interferon beta 1a 56 colorectal cancer liver metastases 56 Kaplan Meier estimate 56 visilizumab 56 keloid scarring 56 Decompensated Heart Failure 56 corticosteroid therapy 56 evaluating tivozanib 56 SUVmax 56 refractory ALCL 56 relapsed myeloma 56 Sutent sunitinib 56 hypoglycemic episodes 56 untreated AML 56 SGPT 56 hypokalemia 56 severe renal impairment 56 cutaneous T 56 #mg/m# [001] 56 oral chemotherapeutic agent 56 RGT arm 56 unresectable HCC 56 severe hypersensitivity reactions 56 SJIA 56 Albuferon TM 56 clodronate 56 MACCE 56 undetectable HCV RNA 56 CHOP chemotherapy 56 ZOLINZA 56 virologic breakthrough 56 intra articular injection 56 Median PFS 56 Zometa hazard 56 previously untreated follicular 56 tumor lysis syndrome 56 mild renal insufficiency 56 alvespimycin 56 Teriflunomide 56 glycosylated hemoglobin HbA1c 56 cancer neuroendocrine tumor 56 mg BID 56 g trans fats 56 Chronic Myelogenous Leukemia CML 56 plus MTX 56 MabThera Rituxan 56 peak plasma concentrations 56 nadroparin 56 patients coinfected 56 acromegalic patients 56 retinal thrombosis hemorrhages 56 prolonged QT interval 56 neutropenic patients 56 headache abdominal pain 56 methotrexate therapy 56 highly emetogenic 56 initiating HUMIRA 56 class mGluR5 inhibitor 56 atherothrombotic events 56 Crofelemer budesonide foam 56 liver metastases 56 tumor necrosis 56 Dose limiting toxicities 56 colorectal bowel 56 nonsmall cell lung cancer 56 mg TID 56 unresectable recurrent 56 dermatologic reactions 56 BRIM3 56 mutated KRAS 56 histologies 56 dose cohort 56 pediatric acute lymphoblastic 56 amoxicillin clavulanate 56 quetiapine Seroquel 56 virus HCV infection 56 urinary N telopeptide 56 plus gemcitabine 56 Jevtana 56 nonvertebral fractures 56 hepatocellular cancer 56 hyperphenylalaninemia HPA due 56 Hepatotoxicity 56 diagnosed Ph + 56 eculizumab therapy 56 cardiovascular calcification 56 biochemical recurrence 56 perioperative complications 56 KRAS wild 56 aminotransferase levels 56 chemotherapy cisplatin 56 transaminase elevation 56 Viral load 56 mg m² 56 prostate cancer CaP 56 reinterventions 56 metastatic CRPC 56 relapsed acute lymphoblastic 56 solid tumors ZYBRESTAT 56 â ‰ ¥ 56 dirucotide MBP# 56 lamivudine refractory patients 56 neutrophil counts 56 DEB# 56 CTA# Injection 56 lumiliximab 56 R lenalidomide 56 Ileus 56 TMP SMX 56 transaminases 56 BCG refractory carcinoma 56 Annamycin 56 samalizumab 56 containing abacavir 56 relapsing multiple sclerosis 56 anagrelide 56 HIV HCV coinfected 56 memantine HCl 56 cell acute lymphoblastic 56 HCV SPRINT 56 T1DM 56 refractory multiple myeloma 56 compound INCB# 56 relapsers 56 chemoradiation therapy 56 hypocalcemia 56 Idiopathic pulmonary fibrosis 56 HER2 expression 56 myeloproliferative diseases 56 #mg q8h 56 candidates Azedra TM 56 plasma uric acid 56 histologic subtype 56 neutropenic fever 56 lung metastasis 56 Impaired glucose tolerance 56 radiographic progression 56 PRN FDA Approves 56 lymphopenia 56 ENL recurrence 56 angiotensin analog 56 Perifosine KRX 56 stage IIIb 56 Peg IFN 56 CIMZIA TM certolizumab pegol 56 Lung transplantation 56 measurable tumor regressions 56 FDA Approves Novel 56 prednisone CHOP 56 achieve sustained virologic 56 antidepressants fluoxetine 56 Amgen Neulasta ® 56 damage cirrhosis liver 56 lung metastases 56 castration resistant prostate cancer 56 coinfected patients 56 arterial thromboembolic events 56 squamous cell lung cancer 56 antiangiogenesis therapies 56 intra abdominal abscess 56 Off Magazines 56 lupus nephritis 56 Solid Tumors criteria 56 discontinuations due 56 AAG geldanamycin analog 56 castrate resistant prostate cancer 56 achieved PASI 56 Fludara ® 56 juvenile idiopathic arthritis 56 nodular partial response 56 oblimersen 56 intravenous bolus 56 non myeloid malignancies 56 non squamous NSCLC 56 Chronic pancreatitis 56 budesonide pMDI 56 octreotide LAR 56 #mg/day [001] 56 Meets Primary Endpoint 56 NNRTI resistance 56 essential thrombocythemia 56 pamidronate 56 Arch Intern Med 56 rectal tenesmus 56 interquartile range 56 hemoglobin A1c levels 56 log# reduction 56 Stage IIIB IV 56 Dementia Related Psychosis 56 rimonabant #mg 56 acute GVHD 56 conventional DMARDs 56 oral picoplatin 56 neutropaenia 56 Peginterferon Alfa 2a 56 Chronic Myeloid Leukemia 56 AA Amyloidosis 56 sunitinib malate 56 FOLPI regimen 56 HNSCC 56 serum calcium levels 56 Median survival 56 MAGE A3 ASCI 56 transaminase elevations 56 IV tPA 56 refractory colorectal cancer 56 baseline HbA1c 56 sorafenib tablets 56 gefitinib Iressa 56 PREZISTA ritonavir 56 platinum refractory 56 infection sinusitis 56 SGOT 56 Peginterferon alfa 2b 56 Expanded Disability Status 56 cytidine nucleoside analog 56 onset seizures 56 non hodgkin lymphoma 56 myocardial reperfusion 56 Severe hypoglycemia 56 TMC# r 56 hepatic metastases 55 Myelodysplasia 55 tumor recurrence 55 imatinib Gleevec 55 null responders 55 sitaxsentan 55 normal ULN 55 IV metastatic melanoma 55 confidence interval #.#-#.# 55 Adenomas 55 artery stenosis 55 peginterferon alfa 55 specific antigen PSA 55 INCB# [003] 55 antidiabetic medication 55 Platinol ® cisplatin 55 clinically localized prostate 55 ALT normalization 55 thalidomide Thalomid 55 UNCERTAINTY OF FUTURE FINANCIAL 55 headache nasopharyngitis 55 HCV NS5B polymerase 55 Ovitrelle R Serostim 55 lumbar spine BMD 55 nonnucleoside reverse transcriptase inhibitors 55 Acetate Rectal Suppositories 55 Injecte . 55 oral antidiabetic medication 55 DETROL LA 55 pediatric malignancies 55 #mg/m# [002] 55 relapsed AML 55 bronchopulmonary dysplasia 55 Untreated mice 55 hematologic adverse 55 hematologic parameters 55 STRIDE PD 55 INVEGA ® 55 Crohn Disease Activity 55 CGuillen Detroit 55 particularly SANCTURA XR 55 intensive statin therapy 55 DAS# CRP 55 fasting plasma glucose FPG 55 PR interval prolongation 55 myelogenous leukemia 55 hypercalcemia 55 colorectal liver metastases 55 TAXUS p value 55 aromatase inhibitor therapy 55 x ULN 55 GRNOPC1 contains 55 adenomatous polyps 55 oral prednisone 55 graft dysfunction 55 liver metastasis 55 autoantibody levels 55 mg RDEA# 55 Raptiva r 55 beta blocker therapy 55 RAS mutations 55 TRAIL induced apoptosis 55 taxane refractory 55 paroxysmal atrial fibrillation 55 IV RSD# 55 abacavir lamivudine 55 neovascular diseases 55 3TC lamivudine Epivir 55 FEMALES SHOULD BE ADVISED 55 castrate resistant 55 untreated metastatic colorectal 55 adjuvant tamoxifen 55 adverse cytogenetics 55 lactate dehydrogenase LDH 55 advanced hepatocellular carcinoma 55 clozapine Clozaril 55 Anthracycline 55 Complicated Skin 55 myeloproliferative neoplasms 55 QTc prolongation 55 BY JOSH SALM 55 glioblastoma tumors 55 AN# topical anti 55 homozygous familial hypercholesterolemia 55 dose cohorts 55 radioiodine therapy 55 β blockers 55 HUMIRA achieved PASI 55 Neovascular AMD 55 R abatacept 55 tipranavir r 55 fatal pulmonary embolism 55 debilitating complication 55 renal cysts 55 By Kemuel Stewart 55 Femara letrozole 55 gastrointestinal GI perforation 55 GvHD 55 AGILECT ® 55 recurrent wheezing 55 low dose Iluvien 55 relapsing MS 55 thymoma 55 systemic immunosuppressive 55 symptomatic VTE 55 hip BMD 55 Sprycel dasatinib